X

Trial Profile

A study to determine tumor-intrinsic and patient-specific immunologic predictors of response to Teclistamab

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teclistamab (Primary)
Indications Multiple myeloma
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

29 Jan 2024 New trial record
12 Dec 2023 According to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition, clinical and translational data from additional patients will be presented at the meeting.
12 Dec 2023 Results (n=52) presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com